Literature DB >> 24159237

Should azithromycin no longer be considered a drug of choice for community-acquired pneumonia because of its potential to cause cardiovascular death?

.   

Abstract

Entities:  

Year:  2013        PMID： 24159237      PMCID： PMC3806423          DOI： 10.4212/cjhp.v66i5.1292

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN： 0008-4123


× No keyword cloud information.
  24 in total

1.  Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society.

Authors:  L A Mandell; T J Marrie; R F Grossman; A W Chow; R H Hyland
Journal:  Can Respir J       Date:  2000 Sep-Oct       Impact factor: 2.409

2.  Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study.

Authors:  J B Muhlestein; J L Anderson; J F Carlquist; K Salunkhe; B D Horne; R R Pearson; T J Bunch; A Allen; S Trehan; C Nielson
Journal:  Circulation       Date:  2000-10-10       Impact factor: 29.690

3.  A case of QT-interval prolongation precipitated by azithromycin.

Authors:  Naohisa Matsunaga; Yasuhiro Oki; Alejandro Prigollini
Journal:  N Z Med J       Date:  2003-11-07

4.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

5.  Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS).

Authors:  Elisabetta Poluzzi; Emanuel Raschi; Ugo Moretti; Fabrizio De Ponti
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-06       Impact factor: 2.890

6.  Cardiovascular risks with azithromycin and other antibacterial drugs.

Authors:  Andrew D Mosholder; Justin Mathew; John J Alexander; Harry Smith; Sumathi Nambiar
Journal:  N Engl J Med       Date:  2013-05-02       Impact factor: 91.245

Review 7.  Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults.

Authors:  Noa Eliakim-Raz; Eyal Robenshtok; Daphna Shefet; Anat Gafter-Gvili; Liat Vidal; Mical Paul; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

8.  Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia.

Authors:  I Martin-Loeches; T Lisboa; A Rodriguez; C Putensen; D Annane; J Garnacho-Montero; M I Restrepo; J Rello
Journal:  Intensive Care Med       Date:  2009-12-02       Impact factor: 17.440

9.  Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial.

Authors:  Christopher M O'Connor; Michael W Dunne; Marc A Pfeffer; Joseph B Muhlestein; Louis Yao; Sandeep Gupta; Rebecca J Benner; Marian R Fisher; Thomas D Cook
Journal:  JAMA       Date:  2003-09-17       Impact factor: 56.272

10.  Use of azithromycin and death from cardiovascular causes.

Authors:  Henrik Svanström; Björn Pasternak; Anders Hviid
Journal:  N Engl J Med       Date:  2013-05-02       Impact factor: 91.245
View more
  1 in total

1.  Risk Evaluation of Azithromycin-Induced QT Prolongation in Real-World Practice.

Authors:  Young Choi; Hong-Seok Lim; Dahee Chung; Jung-Gu Choi; Dukyong Yoon
Journal:  Biomed Res Int       Date:  2018-10-14       Impact factor: 3.411
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.